Published in J Rheumatol on February 01, 2005
Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thromb J (2015) 0.84
Controversies in the antiphospholipid syndrome: can we ever stop warfarin? J Autoimmune Dis (2008) 0.77
Successful Anticoagulation Therapy for Antiphospholipid Syndrome with Mobile Aortic Thrombi. Vasc Specialist Int (2016) 0.75
Immunomodulatory effects of therapeutic plasma exchange on monocytes in antiphospholipid syndrome. Exp Ther Med (2016) 0.75
The challenges of antiphospholipid syndrome: experience from diagnosis to self-care. BMJ Case Rep (2014) 0.75
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med (2015) 3.63
Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum (2007) 3.12
Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2006) 3.11
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med (2012) 3.04
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
RNA aptamers as reversible antagonists of coagulation factor IXa. Nature (2002) 2.73
Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med (2006) 2.68
Venous thromboembolism: a public health concern. Am J Prev Med (2010) 2.37
Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum (2009) 2.33
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum (2003) 2.19
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Ann Intern Med (2013) 2.15
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) (2013) 2.13
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost (2008) 1.61
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol (2013) 1.61
Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood (2010) 1.55
Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum (2006) 1.53
Arterial stiffness in chronic inflammatory diseases. Hypertension (2005) 1.53
Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg (2009) 1.49
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum (2007) 1.43
Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med (2013) 1.39
Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med (2003) 1.38
Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit (2010) 1.36
Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. J Am Coll Cardiol (2013) 1.34
Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol (2005) 1.31
Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease. Psychosom Med (2013) 1.24
Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum (2006) 1.23
High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood (2013) 1.16
Retracted Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood (2005) 1.12
Systemic lupus erythematosus predicts increased left ventricular mass. Circulation (2007) 1.07
The optimal tool for assessment of organ damage in antiphospholipid syndrome. J Rheumatol (2013) 1.07
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.06
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood (2004) 1.06
Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol (2009) 1.05
Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev (2013) 1.04
Coagulation and inflammation in acute lung injury. Thromb Haemost (2002) 1.03
What is antiphospholipid syndrome? Curr Rheumatol Rep (2004) 1.02
Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg (2003) 1.02
Catastrophic antiphospholipid syndrome. J Intensive Care Med (2006) 1.02
Venous thromboembolic disease. J Natl Compr Canc Netw (2013) 1.01
Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg (2005) 1.01
Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. J Thromb Thrombolysis (2012) 1.00
Heparin modifies the immunogenicity of positively charged proteins. Blood (2010) 1.00
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl (2009) 1.00
The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth (2006) 0.98
Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.98
Associations of depressive symptoms, trait hostility, and gender with C-reactive protein and interleukin-6 response after emotion recall. Psychosom Med (2010) 0.98
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol (2007) 0.97
The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol (2007) 0.97
Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol (2002) 0.97
Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum (2006) 0.97
Heparin-induced thrombocytopenia. Annu Rev Med (2010) 0.95
Coagulation abnormalities in patients with hip osteonecrosis. Orthop Clin North Am (2004) 0.95
Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov (2004) 0.95
The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol (2007) 0.95
Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther Adv Musculoskelet Dis (2013) 0.94
Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med (2006) 0.93
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis (2007) 0.91
Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol (2002) 0.91
New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol (2009) 0.91
Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheumatol Rep (2011) 0.91
Lupus and thrombosis. J Rheumatol (2006) 0.90
Thrombophilias: when should we test and how does it help? Semin Respir Crit Care Med (2008) 0.90
A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum (2013) 0.90
Antiphospholipid syndrome. Prog Cardiovasc Dis (2009) 0.89
Churg-strauss syndrome with eosinophilic myocarditis: a clinical pathology conference held by the division of rheumatology at hospital for special surgery. HSS J (2012) 0.89
Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol (2002) 0.89
Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. Thromb Haemost (2012) 0.88
Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thromb Res (2011) 0.88
Cardiac manifestations in the antiphospholipid syndrome. Rheum Dis Clin North Am (2006) 0.88
Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol (2005) 0.87
Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin Rev Allergy Immunol (2009) 0.87
Antithrombotic therapy and invasive procedures. N Engl J Med (2013) 0.87
Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2008) 0.87
Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. J Thromb Thrombolysis (2007) 0.87
Perioperative management of antiphospholipid antibody-positive patients. Curr Rheumatol Rep (2014) 0.87
Pregnancy outcomes following total hip arthroplasty: a preliminary study and review of the literature. Orthopedics (2003) 0.86
Clinical assessment and management of cytopenias in lupus patients. Curr Rheumatol Rep (2011) 0.85
Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group. Am J Med (2011) 0.85
Characterization of the hypercoagulable state in patients with sickle cell disease. Thromb Res (2012) 0.85
Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding. Thromb Haemost (2003) 0.84
Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial (2003) 0.84